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Abstract: This study provides a brief view of chronic pulmonary aspergillosis (CPA) in the post-
tuberculosis treatment community in Vietnam, a high burden tuberculosis (TB) country. In three 
months in late 2019, 70 post-TB patients managed at Vietnam National Lung Hospital were enrolled. 
Of these, 38 (54.3%) had CPA. The male/female ratio was 3/1 (28 males and ten females). CPA pa-
tients had a mean age of 59 ± 2.3 years (95%CI 54.4–63.6). The mean Body mass index (BMI) was 
19.0 ± 0.5 (18.0–20.0) and 16 of 38 (42.1%) patients had concurrent diseases, the most common of 
which were chronic obstructive pulmonary disease (COPD) and diabetes. Twenty-six patients 
(68.4%) developed hemoptysis, 21 (55.3%) breathlessness, and weight loss was seen in 30 (78.9%). 
Anaemia was seen in 15 (39.5%) and 27 of 38 (71.1%) patients had an elevated C-reactive protein 
(CRP). The most common radiological findings were multiple cavities (52.6%) and pleural thicken-
ing (42.7%), followed by aspergilloma (29.0%) and non-specific infiltrates. There were five of 38 
patients (13.2%) with a cavity containing a fungal ball on the chest X-ray, but when the high resolu-
tion computed tomography (HRCT) was examined, the number of patients with fungal balls rose 
to 11 (28.9%). Overall, 34 of 38 (89.5%) cases had an elevated Aspergillus IgG with an optical density 
≥ 1, and in 2 cases, it was 0.9–1.0 (5%), borderline positive. In nine patients (23.7%) Aspergillus fu-
migatus was cultured from sputum. CPA is an under-recognised problem in Vietnam and other high 
burden TB countries, requiring a different diagnostic approach and treatment and careful manage-
ment. HRCT and Aspergillus IgG serum test are recommended as initial diagnostic tools for CPA 
diagnosis. 
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1. Introduction 
TB remains a worldwide health problem with complicated sequelae even after the 
end of treatment [1]. Among TB sequelae, chronic pulmonary aspergillosis (CPA) is the 
most deadly chronic sequela with multiple presentations [2]. CPA can supervene in many 
respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, 
and cystic fibrosis, affecting an estimated 3 million people. TB and probably COPD pa-
tients are the most common predisposing conditions. About one among five post-TB pa-
tients with a cavity will develop CPA after treatment [3]. 
This disease silently destroys lung parenchyma with progressive cavitation, pleural 
thickening, and fibrosis. The usual lack of specific symptoms and a definitive diagnostic 
test leads to high mortality rates, even higher with antifungal drug resistance [4,5]. 
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In limited resources settings and high burden TB countries, CPA diagnosis is com-
monly confused with other diseases, such as smear-negative TB. These errors lead to 
harmful problems in both clinical and epidemiological settings: the slow process of diag-
nosis and treatment, low treatment adherence, and poor outcomes increases the public 
health risk of developing multidrug-resistant TB because of lack of confidence in TB ser-
vices, and waste of healthcare resources [5]. Hence, a good approach and understanding 
of the disease are essential, especially in high burden TB countries [6]. 
Vietnam is ranked 13th among 30 high burden TB countries [1]. Previous studies 
have reported a high burden of fungal infections and also antifungal drug resistance [7]. 
Despite these complications, direct CPA data are lacking in Southeast Asia and Vietnam. 
Hence, we conducted a study with two objectives: to describe the CPA situation among 
post TB patients and to evaluate the prognostic factors of having CPA after PTB, to give a 
preliminary view of CPA in Vietnam, a tropical country with a high TB burden and lim-
ited laboratory diagnostics for fungal disease. 
2. Materials and Methods 
2.1. Patients 
A retrospective observational study was conducted with medical records of patients 
at Vietnam National Lung Hospital from October 2019 to December 2020. All the patients 
were diagnosed based on international guidelines from the European Society for Clinical 
Microbiology and Infectious Diseases and the European Respiratory Society [2,8]. 
All patients with a history of prior TB therapy who presented with abnormal radio-
logical findings and prolonged respiratory symptoms were recruited for this study. The 
patients were diagnosed with CPA if they had the following criteria: (i) presenting with 
clinical features such as prolonged cough, weight loss, bronchiectasis, or hemoptysis last-
ing for at least three months; (ii) radiological findings suggesting any features of CPA, 
including aspergilloma, cavity, multiple cavities, pericavitary infiltrates, thickened pleura 
or fibrosis [9]; (iii) serological or microbiological evidence implicating Aspergillus spp. or 
histopathological evidence [10]. 
We excluded patients with either a history of having antifungal treatment in the last 
two months before the clinical review or active TB. 
2.2. Clinical Samples and Radiological Findings 
Respiratory specimens, including bronchoalveolar lavages (BAL) and sputum, were 
cultured and followed a standard protocol provided by our Vietnam National Reference 
TB Laboratory, located in our hospital, to ensure quality handling. The description of our 
National Reference Laboratory center can be found elsewhere [11]. 
Positive culture for Aspergillus sp. from a respiratory sample (BAL, sputum) and his-
topathology confirmed were taken as solid evidence of CPA. All patients were also tested 
for Mycobacteria spp. using GeneXpert or culture in sputum and BAL to exclude any TB 
relapse. 
All the patients were screened with a chest X-ray and also had a high solution com-
puted tomography (CT) scan of the thorax. An expert panel interpreted the chest X-rays 
and CT scans with experienced pulmonologists and radiologists for consensus on the 
characteristic features of CPA or other conditions. 
2.3. Serology Test 
We tested serum IgG Aspergillus antibodies in all the patients using the Aspergillus 
fumigatus IgG ELISA (enzyme immunoassay (EIA)) (Bordier Affinity Products, Switzer-
land). The specimens’ investigation was done as per the manufacture’s recommendations 
with an optical density (OD) cut-off of 1 for a positive IgG serum level. Moreover, we 
analyzed with the cut-off OD value of 0.9 to find differences between the IgG serum levels 
[12]. 




CPA treatment followed international guidelines (400 mg oral itraconazole (2 cap-
sules) daily after a meal for at least six months in those who agreed to take it. We have not 
collected follow-up data on response (a future study). 
2.5. Statistical Analysis 
We used the STATA® version 13 (STATA, College Station, Texas, USA) for data man-
agement and analysis. The demographic and other features were analyzed by descriptive 
analysis with mean, median, and percentages. All the tests with a p-value < 0.05 were con-
sidered significant. 
2.6. Ethical Issues 
This study was approved by the Vietnam National Lung Hospital Ethical Committee 
and all the recruited patients signed a consent form before study enrollment. 
3. Results 
In total, 70 patients were referred to our hospital because of respiratory symptoms, 
having been treated for TB previously. Among them, 40 (56.7%) patients were diagnosed 
with CPA. Two CPA patients with active TB were excluded. Finally, we had 38 CPA pa-
tients with a history of prior TB. The male/female ratio was 3/1 (28 males and 10 females). 
CPA patients had a mean age of 59 ± 2.29 years (95%CI 54.35–63.64) (minimum 22 years 
and maximum 86 years). Mean BMI was 18.98 ± 0.496 (17.97–19.98). For comorbidities, 
16/38 (42.1%) patients had concurrent diseases. The most common were COPD and dia-
betes (Table 1). Several patients had bronchiectasis (three cases). Cultures for Mycobacteria 
were negative for all species, other than the two excluded above. 
Table 1. The demographic, clinical symptoms, and radiological findings of CPA patients. 
Features No. Statistics 
Baseline demographics 
CPA confirmed cases 40  
Age mean (SD)/Median (IQR) 59 2.3 (54.4–63.6) 
Males 28 73.7% 
Females 10 26.3% 
BMI 19.0 0.49 (18.0–20.0) 
Comorbidities 
Diabetes 5 12.5% 
COPD 8 20% 
Bronchiectasis 3 7.5% 
Interval after TB to CPA presentation 
<5 years 9 27.3% 
5–10 years 10 30.3% 
>10 years 14 42.4% 
Clinical symptoms 
Cough 37 97.4% 
Productive cough 31 81.6% 
Hemoptysis 18 47.4% 
Dyspnea 21 55.3% 
Fever 8 21.1% 
Weight loss 14 36.8% 
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Chest X-ray radiological findings 
Cavitary lesion 8 21.1% 
Aspergilloma 5 13.2% 
Pleural thickening 30 79.0% 
Hemithorax 5 21.1% 
Chest CT findings 
Bilateral 19 50.0% 
Left 7 18.4% 
Right 12 31.6% 
Multiple cavities with thickened pleura 20 52.6% 
Fungal ball(s) (aspergilloma) 11 28.9% 
Single cavity with thickened pleura 6 15.8% 
Pleural thickening 17 44.7% 
Bronchiectasis 10 26.3% 
Non-specific infiltrates 11 28.9% 
 
Ten patients had been treated for recurrent TB once, and three patients had been 
treated for TB three times. Remarkably, 14 of 33 (42.4%) patients had a history of being 
treated for TB more than 10 years previously and 12 (30.3%) 5–10 years previously. Two-
third of CPA patients had previously treated TB more than seven years previously (the 
longest time is 31 years). 
Productive cough was the primary symptom noticed in nearly 100% of patients in 
this study, often with mucus production (n = 37 (97.4%)). Twenty-six patients (68.42%) 
developed hemoptysis, 21 (55.3%) breathlessness, and weight loss was seen in 30 (78.9%). 
Anaemia was seen in about a third of patients—15 (39.5%). 
Culture grew Aspergillus fumigatus in 10 cases, six in sputum, and four from BAL 
specimens. No other species were found. Histopathology findings were characteristic of 
CPA in three patients who underwent lung lobectomy and the other two who had trans-
thoracic lung biopsies. 
Overall, 27 of the 38 (71.1%) patients had an elevated C-reactive protein (CRP) (Table 
2). All patients were tested for Aspergillus IgG (Table 2). 
Table 2. The laboratory parameters of CPA patients. 
Blood Test Mean/Median SD/IQR  Normal Range 
WBC 10.6 4.9  4.5–11. 0 
CRP 60.9 71.7 0–5.0 
Aspergillus IgG 2.82 1.9  <0.9 
Overall, 34 of 38 (89.5%) cases had an Aspergillus IgG optical density ≥ 1, and in four 
cases, IgG was less than 1 (10.5%). The mean IgG OD was 2.82 ± 1.9. There were four cases 
with an Aspergillus IgG < 1. One case had lung lobectomy, so confirmed histopathologi-
cally. Others were confirmed with Aspergillus in sputum and BAL culture (in one case, the 
Aspergillus IgG OD was 0.978, and two others were 0.482 and 0.738). If the OD threshold 
was reduced to 0.9, two more cases were defined as CPA using serology (94.7%) (Figure 1). 




Figure 1. Summary of Aspergillus IgG distribution. 
We found a slight correlation between the duration of TB infection and Aspergillus 
IgG levels (p-value = 0.005) (Figure 2). However, the R squared is low (0.01), indicating 
that the height of the Aspergillus IgG antibody response is only slightly influenced by time. 
 
Figure 2. The correlation between Aspergillus IgG level and years of TB history. 
With regard to the radiological findings, half of the patients had bilateral damage, 
31.9% had damage on the right side, and the remainder only on the left. The most common 
findings were multiple cavities (52.6%) and pleural thickening (42.7%), followed by asper-
gilloma (29.0%) and infiltrates. Five of the 38 patients (13.2%) had a cavity containing a 
fungal ball on the chest X-ray, but when the HRCT was examined, the number of patients 
with fungal balls rose to 11 (28.9%). (Figure 3). 




Figure 3. Typical computed tomography findings in our CPA patients. (A,B) were from a 71-year-
old male patient, (C,D) were of a 50-year-old male patient, and (E,F) were from a 78-year-old female 
patient. (A) (contrast enhanced scan) shows enlarged arterial vessels on the edge of two separate 
cavities posteriorly in the right lung. The lung windows from a slightly higher section show a large 
thick-walled cavity with an irregular interior lining, and probably three other much smaller cavities, 
in association with remarkable pleural thickening posteriorly, with some pleural fat latero-posteri-
orly. No aspergilloma is visible in either image. (C) shows extensive pleuro-pulmonary fibrosis en-
casing the right upper lung, with two small cavities (probably) anteriorly. The right main bronchus 
and mediastinum is shifted to the right. In (D), slightly higher in the chest at the level of the aortic 
arch, shows considerable major arterial blood vessel distortion, additional enlarged arteries within 
the areas of inflammation or fibrosis and an anterior cavity. (E) shows at least one thick-walled cav-
ity at the top of the left overlying an area of significant pleural thickening, with areas of consolida-
tion or fibrosis anteriorly, containing some calcification on a bullous emphysematous background. 
There is a small area of ill-defined inflammation in the right lung. The bronchial walls contain sig-
nificant calcification. (F) also shows the major mediastinal shift to the left, with extensive areas of 
consolidation or fibrosis with no particular pattern. 
Following evaluation in clinic, and with all the results available to treating physi-
cians, 21 (55.2%) patients were treated with itraconazole therapy. However, we did not 
collect follow-up information. 
4. Discussion 
CPA is a complicated pulmonary syndrome that requires a careful approach in diag-
nosis, treatment, and management. This is the first descriptive study from Vietnam to 
provide a brief view of the clinical spectrum and associated factors of CPA in the post-TB 
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population. A recent attempt to quantify the likely prevalence of CPA in Vietnam esti-
mated 55,500 affected people, 61 per 100,000, which is an internationally high rate. Post-
tuberculous cavitation is common in Vietnam at 41% [13–15]. 
In this study, we highlighted the features/clinical symptoms of CPA among post-tu-
berculosis patients. This is the first study to describe the characteristics of CPA among the 
post-TB community in Southeast (SE) Asia. This study provides essential material for de-
veloping a national guideline for diagnosing, treating, and managing CPA. 
Most of the patients we identified with CPA were older than 50, mean age 59 ± 2.25 
years. This is similar to other studies, where CPA is most often reported mostly in middle-
aged patients. In a previous study, age has been reported as a risk factor for poor outcomes 
in CPA TB patients [16]. The link with older age may be partially explained by the chronic 
development of CPA [3], but some comorbidities were also found; 10% of our patients 
had at least one comorbidity, mostly COPD or diabetes. Diabetes has been described as a 
significant association with CPA, as reported in several previous studies [16–18]. Diabetes 
is also considered a risk factor for developing a cavity during pulmonary TB and may be 
a risk factor for developing CPA [19–21]. In low-burden TB countries, other common risk 
factors are COPD and prior pulmonary surgery history [19,22]. However, in our study, 
only 20% of CPA patients had a COPD history. With a COPD prevalence of 6.7% and a 
population of 100 million [23], it is also essential to consider CPA as a differential diagno-
sis for TB among COPD patients in Vietnam. A holistic approach and screening for comor-
bidities in CPA patients is also required. 
Furthermore, when screening people with a history of prior TB, we found two pa-
tients with positive TB tests who had concurrent CPA. Even with the exclusion of these 
patients due to the mimicking of symptoms and radiological findings, this interesting 
finding indicates that Aspergillus and Mycobacterium can combine to damage the lung. He-
dayati in Iran and Iqbal in Pakistan reported that 13.7% and 13% of patients with CPA 
were co-infected with M. tuberculosis, respectively [18,24]. 
Hence, we recommend that every patient with PTB, active or with a prior history, 
should be screened for CPA to prevent the possibility of having a co-infection, especially 
if symptoms persist despite anti-tuberculous therapy. 
Our data should raise awareness of CPA and the need to consider other respiratory 
diseases with similar non-specific symptoms. CPA is being underestimated and often con-
fused with another chronic pulmonary disease, especially smear-negative TB [2]. The 
years of misdiagnosis of tuberculosis and incorrect treatment is addressable with clinical 
training and testing for fungal disease and aspergillosis. 
In our study among post-TB patients, 56.7% were found to have only CPA and 2.9% 
had CPA and PTB, using criteria proposed for low resource settings [2]. This result is 
higher than similar studies in Uganda [6,25]. It can be explained by our small sample size. 
Globally, the prevalence of CPA among post TB patients ranged from 21–35%, depending 
on country situation [25]. What we cannot know is how many patients died of CPA, mis-
diagnosed as TB, and therefore could not have been referred for evaluation. The cohort 
seen in our center are probably the ‘slow progressors’, and much more aggressive CPA is 
likely to have been fatal [26]. 
Most of the CPA patients we identified developed CPA at least two years after treat-
ment for PTB. The history of TB treatment is discussed in other studies [18]. Previous 
studies have reported higher percentages of having CPA after PTB treatment than patients 
just finishing complete therapy [3]. CPA development over time can explain this even 
after TB treatment. The interval between completing TB therapy and development of CPA 
is often many years. Suspicion and early diagnosis of CPA is important as five-year mor-
tality rates are 50% even with treatment [2]. 
Prolonged cough with mucus and hemoptysis are the most common symptoms of 
CPA, followed by weight loss and fever [27]. Although cough and hemoptysis are typical, 
they are not reliable symptoms alone for CPA diagnosis as several other conditions in-
cluding bronchiectasis and PTB have these manifestations. Symptoms lasting longer than 
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three months is a clue for clinicians to think about CPA [2,12]. Otherwise, progression and 
death are common [28,29]. 
A CT scan is recommended as an initial diagnostic aid tool when CPA is clinically 
considered, providing better and more precise information than X-rays [30–32]. Over 50% 
of our patients had bilateral damage, and right-sided damage is more common than the 
left, consistent with the TB damage. 
Unlike invasive pulmonary aspergillosis in which the specific halo sign can often be 
seen, the CPA radiological findings include aspergilloma, multiple cavities, and pleural 
thickening or necrotizing development [33]. Radiographic CT scan features secondary to 
Aspergillus infection range from a typical appearance of a fungus ball within the lung cav-
ity to complex pleuro-parenchymal features related to the progressive destructive cavi-
tary disease. Our study’s most common manifestation was multiple cavities, similar to 
other reviews [12,34]. Typical radiological findings have been described elsewhere. 
[35,36]. It is difficult to distinguish CPA from other cavitary diseases such as tuberculosis, 
chronic cavitary pulmonary histoplasmosis, bronchiectasis, or even a combination of these 
conditions. In a few select cases, when Aspergillus develops into a fungal ball in a cavity, 
we can see an unusual type of CPA with a cavity with a crescent moon inside surrounding 
a fungal ball [35]. 
The role of Aspergillus IgG has been reported in previous studies [2,3,37]. This test is 
often considered the gold standard test for CPA diagnosis and is valuable for tracking the 
disease’s progression with a high positive predictive value [11,22]. In an Indonesian study, 
the Aspergillus IgG was a convenient tool with good diagnostic performance and simple 
application [3]. In most studies, Aspergillus IgG is positive in 80–92% of CPA cases, and 
we had two false negative tests in our patients. 
An approach using clinical symptoms and Aspergillus IgG would be the initial screen 
for diagnosing CPA [38,39]. Our study also found a high level of IgG associated with a 
history of prior PTB, similar to previous studies, where active TB patients do not have an 
elevated IgG level [17]. As CPA can silently develop after completion of TB treatment, 
annual CPA evaluation including Aspergillus IgG to check seems appropriate. 
Some of our patients were treated with antifungals: 400 mg itraconazole daily follow-
ing international guidelines. This treatment is effective in some studies [40]. However, 
nearly half of the CPA patients did not receive any specific treatment. Our clinicians are 
poorly educated when approaching CPA patients, hence the poor uptake of self-funded 
antifungal therapy. More education and a national guideline is needed to raise the alert-
ness of clinicians about fungal diseases. 
Furthermore, in our country setting, a question arises about the azole-resistant situ-
ation since Justin Bearsley reported an extraordinary prevalence of drug-resistant Asper-
gilli in Vietnam [5]. Further studies should evaluate the frequency and risk of azole-re-
sistance in the future. 
Our study has some limitations. We only conducted a retrospective study, which had 
limited information and may suffer from recall bias. Another problem is the small number 
of patients, which may not be generalizable across the country. However, this study could 
be considered a cornerstone, along with previous studies, to raise awareness and improve 
clinical practice of CPA among the PTB community. Further research on the CPA situation 
in Vietnam is necessary to address potential problems such as drug-resistance in fungi. 
Author Contributions: Conceptualization, N.T.B.N., D.W.D., H.LN., and N.V.N., methodology, 
H.V.N., N.V.N., and H.T.N., validation, N.T.B.N., L.V.D., H.L.N., and H.T.N.; formal analysis, 
N.T.B.N. and H.LN.; investigation, N.T.B.N. and H.T.N.; writing—original draft preparation, 
N.T.B.N. and H.LN.; writing—review and editing, D.W.D., N.V.N., and L.V.D. All authors have 
read and agreed to the published version of the manuscript. 
Funding: This research received no external funding. 
J. Fungi 2021, 7, 532 9 of 10 
 
 
Institutional Review Board Statement: The study was conducted according to the guidelines of the 
Declaration of Helsinki, and approved by the local Ethics Committee of Vietnam National Lung 
Hospital (559/2020/NCKH) 
Informed Consent Statement: Informed consent was obtained from all subjects involved in the 
study. 
Acknowledgments: The authors are thankful to the doctors at Vietnam National Lung Hospital for 
their kind support in patient recruitment and management. 
Conflicts of Interest: The authors declare no conflicts of interest. 
References 
1. World Health Organization. Global Tuberculosis Report 2019; Geneva:World Health Organization: 2019; ISBN 978-92-4-156571-4. 
2. Denning, D.W.; Cadranel, J.; Beigelman-Aubry, C.; Ader, F.; Chakrabarti, A.; Blot, S.; Ullmann, A.J.; Dimopoulos, G.; Lange, C. 
European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society Chronic pulmonary as-
pergillosis: Rationale and clinical guidelines for diagnosis and management. Eur. Respir. J. 2016, 47, 45–68. 
3. Rozaliyani, A.; Rosianawati, H.; Handayani, D.; Agustin, H.; Zaini, J.; Syam, R.; Adawiyah, R.; Tugiran, M.; Setianingrum, F.; 
Burhan, E.; et al. Chronic Pulmonary Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus 
ICT as Part of the Diagnosis Scheme. J. Fungi 2020, 6, 318. 
4. Harries, A.D.; Dlodlo, R.A.; Brigden, G.; Mortimer, K.; Jensen, P.; Fujiwara, P.I.; Castro, J.L.; Chakaya, J.M. Should we consider 
a “fourth 90” for tuberculosis? Int. J. Tuberc. Lung Dis. 2019, 23, 1253–1256. 
5. Beardsley, J.; Denning, D.W.; Chau, N.V.; Yen, N.T.B.; Crump, J.A.; Day, J.N. Estimating the burden of fungal disease in Vi-
etnam. Mycoses 2015, 58 (Suppl. 5), 101–106. 
6. Bongomin, F.; Kwizera, R.; Atukunda, A.; Kirenga, B.J. Cor pulmonale complicating chronic pulmonary aspergillosis with fatal 
consequences: Experience from Uganda. Med. Mycol. Case Rep. 2019, 25, 22–24. 
7. (PDF) Unprecedented Prevalence of Azole-Resistant Aspergillus Fumigatus Identified in the Environment of Vietnam, with 
Marked Variability by Land Use Type. Available online: https://www.researchgate.net/publication/346424769_Unprece-
dented_Prevalence_of_Azole-Resistant_Aspergillus_fumigatus_Identified_in_the_Environment_of_Vi-
etnam_with_Marked_Variability_by_Land_Use_Type (accessed on 11 March 2021). 
8. Diagnosis and Management of Aspergillus Diseases: Executive Summary of the 2017 ESCMID-ECMM-ERS Guideline—Clinical 
Microbiology and Infection. Available online: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(18)30051-
X/fulltext (accessed on 11 March 2021). 
9. Denning, D.W.; Page, I.D.; Chakaya, J.; Jabeen, K.; Jude, C.M.; Cornet, M.; Alastruey-Izquierdo, A.; Bongomin, F.; Bowyer, P.; 
Chakrabarti, A.; et al. Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerg. Infect. Dis. 
2018, 24. doi:10.3201/eid2408.171312. 
10. Oladele, R.; Otu, A.A.; Olubamwo, O.; Makanjuola, O.B.; Ochang, E.A.; Ejembi, J.; Irurhe, N.; Ajanaku, I.; Ekundayo, H.A.; 
Olayinka, A.; et al. Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria. 
Pan Afr. Med. J. 2020, 36,297. doi:10.11604/pamj.2020.36.297.23279. 
11. Le, H.N.; Sriplung, H.; Chongsuvivatwong, V.; Nguyen, N.V.; Nguyen, T.H. The accuracy of tuberculous meningitis diagnostic 
tests using Bayesian latent class analysis. J. Infect. Dev. Ctries. 2020, 14, 479–487. 
12. Beltrán Rodríguez, N.; San Juan-Galán, J.L.; Fernández Andreu, C.M.; María Yera, D.; Barrios Pita, M.; Perurena Lancha, M.R.; 
Velar Martínez, R.E.; Illnait Zaragozí, M.T.; Martínez Machín, G.F. Chronic Pulmonary Aspergillosis in Patients with Underly-
ing Respiratory Disorders in Cuba-A Pilot Study. J. Fungi 2019, 5,18. doi:10.3390/jof5010018. 
13. Thwaites, G.; Caws, M.; Chau, T.T.H.; D’Sa, A.; Lan, N.T.N.; Huyen, M.N.T.; Gagneux, S.; Anh, P.T.H.; Tho, D.Q.; Torok, E.; et 
al. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuber-
culosis. J. Clin. Microbiol. 2008, 46, 1363–1368. 
14. Thorson, A.; Long, N.H.; Larsson, L.O. Chest X-ray findings in relation to gender and symptoms: A study of patients with smear 
positive tuberculosis in Vietnam. Scand. J. Infect. Dis. 2007, 39, 33–37. 
15. Thanh, N.P.; Khue, P.M.; Sy, D.N.; Strobel, M. Diabetes among new cases of pulmonary tuberculosis in Hanoï, Vietnam. Bull. 
Soc. Pathol. Exot. 1990 2015, 108, 337–341. 
16. Setianingrum, F.; Rozaliyani, A.; Syam, R.; Adawiyah, R.; Tugiran, M.; Sari, C.Y.I.; Burhan, E.; Wahyuningsih, R.; Rautemaa-
Richardson, R.; Denning, D.W. Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary 
aspergillosis (CPA) in Indonesia. Diagn. Microbiol. Infect. Dis. 2020, 98, 115124. 
17. Lee, M.-R.; Huang, H.-L.; Chen, L.-C.; Yang, H.-C.; Ko, J.-C.; Cheng, M.-H.; Chong, I.-W.; Lee, L.-N.; Wang, J.-Y.; Dimopoulos, 
G. Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate 
burden of tuberculosis: A prospective observational study. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. 2020, 26, e1–e1091. 
doi:10.1016/j.cmi.2019.12.009. 
18. Iqbal, N.; Irfan, M.; Zubairi, A.B.S.; Jabeen, K.; Awan, S.; Khan, J.A. Clinical manifestations and outcomes of pulmonary asper-
gillosis: Experience from Pakistan. BMJ Open Respir. Res. 2016, 3, e000155. 
J. Fungi 2021, 7, 532 10 of 10 
 
 
19. Denning, D.W.; Riniotis, K.; Dobrashian, R.; Sambatakou, H. Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergil-
losis: Case Series, Proposed Nomenclature Change, and Review. Clin. Infect. Dis. 2003, 37, S265–S280. 
20. Baker, M.A.; Harries, A.D.; Jeon, C.Y.; Hart, J.E.; Kapur, A.; Lönnroth, K.; Ottmani, S.-E.; Goonesekera, S.D.; Murray, M.B. The 
impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med. 2011, 9, 81. 
21. Iqbal, N.; Irfan, M.; Jabeen, K.; Kazmi, M.M.; Tariq, M.U. Chronic pulmonary mucormycosis: An emerging fungal infection in 
diabetes mellitus. J. Thorac. Dis. 2017, 9, E121–E125. 
22. Hayes, G.E.; Novak-Frazer, L. Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going? J. Fungi 2016, 2, 18. 
23. Ngo, C.Q.; Phan, D.M.; Vu, G.V.; Dao, P.N.; Phan, P.T.; Chu, H.T.; Nguyen, L.H.; Vu, G.T.; Ha, G.H.; Tran, T.H.; et al. Inhaler 
Technique and Adherence to Inhaled Medications among Patients with Acute Exacerbation of Chronic Obstructive Pulmonary 
Disease in Vietnam. Int. J. Environ. Res. Public. Health 2019, 16, 185. 
24. Hedayati, M.T.; Azimi, Y.; Droudinia, A.; Mousavi, B.; Khalilian, A.; Hedayati, N.; Denning, D.W. Prevalence of chronic pul-
monary aspergillosis in patients with tuberculosis from Iran. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 
2015, 34, 1759–1765. doi:10.1007/s10096-015-2409-7 
25. Denning, D.W.; Pleuvry, A.; Cole, D.C. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. 
Bull. World Health Organ. 2011, 89, 864–872. 
26. Tashiro, T.; Izumikawa, K.; Tashiro, M.; Morinaga, Y.; Nakamura, S.; Imamura, Y.; Miyazaki, T.; Kakeya, H.; Yamamoto, Y.; 
Yanagihara, K.; et al. A Case Series of Chronic Necrotizing Pulmonary Aspergillosis and a New Proposal. Jpn. J. Infect. Dis. 2013, 
66, 312–316. 
27. Schweer, K.E.; Bangard, C.; Hekmat, K.; Cornely, O.A. Chronic pulmonary aspergillosis. Mycoses 2014, 57, 257–270. 
28. Takazono, T.; Izumikawa, K. Recent Advances in Diagnosing Chronic Pulmonary Aspergillosis. Front. Microbiol. 2018, 9, 1810. 
29. Jewkes, J.; Kay, P.H.; Paneth, M.; Citron, K.M. Pulmonary aspergilloma: Analysis of prognosis in relation to haemoptysis and 
survey of treatment. Thorax 1983, 38, 572–578. 
30. Prasad, A.; Agarwal, K.; Deepak, D.; Atwal, S.S. Pulmonary Aspergillosis: What CT can Offer Before it is too Late! J. Clin. Diagn. 
Res. JCDR 2016, 10, TE01–TE05. 
31. Gotway, M.B.; Dawn, S.K.; Caoili, E.M.; Reddy, G.P.; Araoz, P.A.; Webb, W.R. The radiologic spectrum of pulmonary Aspergil-
lus infections. J. Comput. Assist. Tomogr. 2002, 26, 159–173. 
32. Godet, C.; Laurent, F.; Bergeron, A.; Ingrand, P.; Beigelman-Aubry, C.; Camara, B.; Cottin, V.; Germaud, P.; Philippe, B.; Pison, 
C.; et al. CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis. Chest 2016, 150, 139–147. 
33. Maghrabi, F.; Denning, D.W. The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre 
Approach. Curr. Fungal Infect. Rep. 2017, 11, 242–251. 
34. Clinical Features and Diagnosis of Chronic Pulmonary Aspergillosis in Chinese Patients. Available online: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662405/ (accessed on 9 March 2021). 
35. Raveendran, S.; Lu, Z. CT findings and differential diagnosis in adults with invasive pulmonary aspergillosis. Radiol. Infect. Dis. 
2018, 5, 14–25. 
36. Page, I. D., Byanyima, R., Hosmane, S., Onyachi, N., Opira, C., Richardson, M., Sawyer, R., Sharman, A., & Denning, D. W. 
(2019). Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. The 
European respiratory journal, 53(3), 1801184. doi:10.1183/13993003.01184-2018 
37. Page, I.D.; Richardson, M.D.; Denning, D.W. Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic 
pulmonary aspergillosis (CPA). J. Infect. 2016, 72, 240–249. 
38. Li, H.; Rui, Y.; Zhou, W.; Liu, L.; He, B.; Shi, Y.; Su, X. Role of the Aspergillus-Specific IgG and IgM Test in the Diagnosis and 
Follow-Up of Chronic Pulmonary Aspergillosis. Front. Microbiol. 2019, 10, 1438. 
39. Richardson, M.D.; Page, I.D. Aspergillus serology: Have we arrived yet? Med. Mycol. 2017, 55, 48–55. 
40. Alastruey-Izquierdo, A.; Cadranel, J.; Flick, H.; Godet, C.; Hennequin, C.; Hoenigl, M.; Kosmidis, C.; Lange, C.; Munteanu, O.; 
Page, I.; et al. Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respir. Int. Rev. 
Thorac. Dis. 2018, 96, 159–170. doI:10.1159/00048947 
 
